Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Nuclear eIF4E Stimulates 3'-End Cleavage of Target RNAs.

Davis MR, Delaleau M, Borden KLB.

Cell Rep. 2019 Apr 30;27(5):1397-1408.e4. doi: 10.1016/j.celrep.2019.04.008.

2.

CDK9 and mTOR: trading places.

Borden KLB.

Blood. 2019 Mar 14;133(11):1167-1168. doi: 10.1182/blood-2019-01-895086. No abstract available.

3.

GLI1-Inducible Glucuronidation Targets a Broad Spectrum of Drugs.

Zahreddine HA, Culjkovic-Kraljacic B, Gasiorek J, Duchaine J, Borden KLB.

ACS Chem Biol. 2019 Mar 15;14(3):348-355. doi: 10.1021/acschembio.8b01118. Epub 2019 Feb 19.

PMID:
30763062
4.

Biochemical and Structural Insights into the Eukaryotic Translation Initiation Factor eIF4E.

Volpon L, Osborne MJ, Borden KLB.

Curr Protein Pept Sci. 2019;20(6):525-535. doi: 10.2174/1389203720666190110142438.

PMID:
30636602
5.

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.

Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, Carroll MP, Carroll AJ, Heerema NA, Devidas M, Dreyer ZE, Hilden JM, Hunger SP, Willman CL, Borden KLB, Felix CA.

Oncogene. 2019 Mar;38(13):2241-2262. doi: 10.1038/s41388-018-0567-7. Epub 2018 Nov 26.

6.

The Impact of Post-transcriptional Control: Better Living Through RNA Regulons.

Culjkovic-Kraljacic B, Borden KLB.

Front Genet. 2018 Nov 5;9:512. doi: 10.3389/fgene.2018.00512. eCollection 2018. Review.

7.

Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.

Osborne MJ, Coutinho de Oliveira L, Volpon L, Zahreddine HA, Borden KLB.

J Mol Biol. 2019 Jan 18;431(2):258-272. doi: 10.1016/j.jmb.2018.11.007. Epub 2018 Nov 11.

PMID:
30428301
8.

Chemical shift assignment of the viral protein genome-linked (VPg) from potato virus Y.

Coutinho de Oliveira L, Volpon L, Osborne MJ, Borden KLB.

Biomol NMR Assign. 2019 Apr;13(1):9-13. doi: 10.1007/s12104-018-9842-3. Epub 2018 Sep 21.

PMID:
30242622
9.

BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.

Ngeow KC, Friedrichsen HJ, Li L, Zeng Z, Andrews S, Volpon L, Brunsdon H, Berridge G, Picaud S, Fischer R, Lisle R, Knapp S, Filippakopoulos P, Knowles H, Steingrímsson E, Borden KLB, Patton EE, Goding CR.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8668-E8677. doi: 10.1073/pnas.1810498115. Epub 2018 Aug 27.

10.

A TFEB nuclear export signal integrates amino acid supply and glucose availability.

Li L, Friedrichsen HJ, Andrews S, Picaud S, Volpon L, Ngeow K, Berridge G, Fischer R, Borden KLB, Filippakopoulos P, Goding CR.

Nat Commun. 2018 Jul 11;9(1):2685. doi: 10.1038/s41467-018-04849-7.

11.

Backbone assignment of the apo-form of the human C-terminal domain of UDP-glucuronosyltransferase 1A (UGT1A).

Osborne MJ, Coutinho de Oliveira L, Volpon L, Borden KLB.

Biomol NMR Assign. 2018 Oct;12(2):315-318. doi: 10.1007/s12104-018-9830-7. Epub 2018 Jun 22.

PMID:
29934866
12.

The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity.

Zahreddine HA, Culjkovic-Kraljacic B, Emond A, Pettersson F, Midura R, Lauer M, Del Rincon S, Cali V, Assouline S, Miller WH, Hascall V, Borden KL.

Elife. 2017 Nov 7;6. pii: e29830. doi: 10.7554/eLife.29830.

13.

A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export machinery.

Volpon L, Culjkovic-Kraljacic B, Sohn HS, Blanchet-Cohen A, Osborne MJ, Borden KLB.

RNA. 2017 Jun;23(6):927-937. doi: 10.1261/rna.060137.116. Epub 2017 Mar 21.

14.

The eukaryotic translation initiation factor eIF4E wears a "cap" for many occasions.

Borden KL.

Translation (Austin). 2016 Aug 10;4(2):e1220899. doi: 10.1080/21690731.2016.1220899. eCollection 2016.

15.

Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E.

Volpon L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, Sun Q, Niesman A, Chook YM, Borden KL.

Proc Natl Acad Sci U S A. 2016 May 10;113(19):5263-8. doi: 10.1073/pnas.1524291113. Epub 2016 Apr 25.

16.

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL, Patel J, Taldone T, Chiosis G, Ladetto M, Ghione P, Machiorlatti R, Elemento O, Inghirami G, Melnick A, Borden KL, Cerchietti L.

Blood. 2016 Feb 18;127(7):858-68. doi: 10.1182/blood-2015-05-645069. Epub 2015 Nov 24.

17.

Multiple Export Mechanisms for mRNAs.

Delaleau M, Borden KL.

Cells. 2015 Aug 28;4(3):452-73. doi: 10.3390/cells4030452. Review.

18.

Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.

Zahreddine HA, Borden KL.

Clin Cancer Res. 2015 May 15;21(10):2207-10. doi: 10.1158/1078-0432.CCR-14-1370. Epub 2015 Mar 25.

19.

Sonic Hedgehog factor Gli1: As good as resistant.

Zahreddine HA, Culjkovic-Kraljacic B, Borden KL.

Mol Cell Oncol. 2015 Feb 24;2(1):e961827. doi: 10.4161/23723548.2014.961827. eCollection 2015 Jan-Mar.

20.

The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.

Osborne MJ, Borden KL.

Immunol Rev. 2015 Jan;263(1):210-23. doi: 10.1111/imr.12240. Review.

21.

Inducible drug modification: a new form of resistance.

Culjkovic-Kraljacic B, Zahreddine HA, Borden KL.

Cell Cycle. 2014;13(16):2485-6. doi: 10.4161/15384101.2014.946372. No abstract available.

22.

When will resistance be futile?

Borden KL.

Cancer Res. 2014 Dec 15;74(24):7175-80. doi: 10.1158/0008-5472.CAN-14-2607. Epub 2014 Dec 4. Review.

23.

A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.

Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH Jr, Borden KL.

Haematologica. 2015 Jan;100(1):e7-9. doi: 10.3324/haematol.2014.111245. Epub 2014 Nov 25. No abstract available.

24.

MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL.

Landon AL, Muniandy PA, Shetty AC, Lehrmann E, Volpon L, Houng S, Zhang Y, Dai B, Peroutka R, Mazan-Mamczarz K, Steinhardt J, Mahurkar A, Becker KG, Borden KL, Gartenhaus RB.

Nat Commun. 2014 Nov 18;5:5413. doi: 10.1038/ncomms6413.

25.

TIF-90 tips the balance in rRNA synthesis.

Borden KL.

Blood. 2014 Jul 24;124(4):467-8. doi: 10.1182/blood-2014-06-578914. No abstract available.

26.

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.

Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, Miller WH, Borden KL.

Nature. 2014 Jul 3;511(7507):90-3. doi: 10.1038/nature13283. Epub 2014 May 28.

27.

LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase.

Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, Carolin AS, Speicher DW, Skordalakes E, Huang Q, Dedhar S, Borden KLB, Rauscher FJ 3rd.

Cancer Res. 2014 Mar 1;74(5):1390-1403. doi: 10.1158/0008-5472.CAN-13-1275.

28.

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, Gascoyne RD, Borden KL, Inghirami G, Leonard JP, Melnick A, Cerchietti L.

Cancer Discov. 2013 Sep;3(9):1002-19. doi: 10.1158/2159-8290.CD-13-0117. Epub 2013 Aug 16.

29.

eIF4E3, a new actor in mRNA metabolism and tumor suppression.

Volpon L, Osborne MJ, Culjkovic-Kraljacic B, Borden KL.

Cell Cycle. 2013 Apr 15;12(8):1159-60. doi: 10.4161/cc.24566. Epub 2013 Apr 9. No abstract available.

30.

Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate.

Volpon L, Osborne MJ, Zahreddine H, Romeo AA, Borden KL.

Biochem Biophys Res Commun. 2013 May 10;434(3):614-9. doi: 10.1016/j.bbrc.2013.03.125. Epub 2013 Apr 10.

31.

Aiding and abetting cancer: mRNA export and the nuclear pore.

Culjkovic-Kraljacic B, Borden KL.

Trends Cell Biol. 2013 Jul;23(7):328-35. doi: 10.1016/j.tcb.2013.03.004. Epub 2013 Apr 10. Review.

32.

Mechanisms and insights into drug resistance in cancer.

Zahreddine H, Borden KL.

Front Pharmacol. 2013 Mar 14;4:28. doi: 10.3389/fphar.2013.00028. eCollection 2013.

33.

The oncogene eIF4E: using biochemical insights to target cancer.

Carroll M, Borden KL.

J Interferon Cytokine Res. 2013 May;33(5):227-38. doi: 10.1089/jir.2012.0142. Epub 2013 Mar 8. Review.

34.

The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia.

Hariri F, Arguello M, Volpon L, Culjkovic-Kraljacic B, Nielsen TH, Hiscott J, Mann KK, Borden KL.

Leukemia. 2013 Oct;27(10):2047-55. doi: 10.1038/leu.2013.73. Epub 2013 Mar 7.

35.

eIF4E3 acts as a tumor suppressor by utilizing an atypical mode of methyl-7-guanosine cap recognition.

Osborne MJ, Volpon L, Kornblatt JA, Culjkovic-Kraljacic B, Baguet A, Borden KL.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3877-82. doi: 10.1073/pnas.1216862110. Epub 2013 Feb 19.

36.

The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation.

Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden KL.

Cell Rep. 2012 Aug 30;2(2):207-15. doi: 10.1016/j.celrep.2012.07.007. Epub 2012 Aug 16.

37.

RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.

Romeo Y, Moreau J, Zindy PJ, Saba-El-Leil M, Lavoie G, Dandachi F, Baptissart M, Borden KLB, Meloche S, Roux PP.

Oncogene. 2013 Jun 13;32(24):2917-2926. doi: 10.1038/onc.2012.312. Epub 2012 Jul 16.

38.

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML).

Assouline S, Cocolakis E, Borden KL.

Cancers (Basel). 2012 Nov 2;4(4):1161-79. doi: 10.3390/cancers4041161.

39.

Structural insights into the allosteric effects of 4EBP1 on the eukaryotic translation initiation factor eIF4E.

Siddiqui N, Tempel W, Nedyalkova L, Volpon L, Wernimont AK, Osborne MJ, Park HW, Borden KL.

J Mol Biol. 2012 Feb 3;415(5):781-92. doi: 10.1016/j.jmb.2011.12.002. Epub 2011 Dec 9.

40.

Targeting the oncogene eIF4E in cancer: From the bench to clinical trials.

Borden KL.

Clin Invest Med. 2011 Dec 1;34(6):E315.

PMID:
22129918
41.

mRNA export and cancer.

Siddiqui N, Borden KL.

Wiley Interdiscip Rev RNA. 2012 Jan-Feb;3(1):13-25. doi: 10.1002/wrna.101. Epub 2011 Jul 27. Review.

PMID:
21796793
42.

Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.

Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KL, Benz CC, Miller WH Jr.

Clin Cancer Res. 2011 May 1;17(9):2874-84. doi: 10.1158/1078-0432.CCR-10-2334. Epub 2011 Mar 17. Erratum in: Clin Cancer Res. 2011 Nov 1;17(21):6952. Retrouvay, Hélène [corrected to Retrouvey, Hélène].

43.

Activation loop phosphorylation of ERK3/ERK4 by group I p21-activated kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated protein kinase 5 signaling pathway.

Déléris P, Trost M, Topisirovic I, Tanguay PL, Borden KL, Thibault P, Meloche S.

J Biol Chem. 2011 Feb 25;286(8):6470-8. doi: 10.1074/jbc.M110.181529. Epub 2010 Dec 22.

44.

Cell biology. Puzzled by PML.

Culjkovic-Kraljacic B, Borden KL.

Science. 2010 Nov 26;330(6008):1183-4. doi: 10.1126/science.1199405. No abstract available.

PMID:
21109655
45.

Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Borden KL, Culjkovic-Kraljacic B.

Leuk Lymphoma. 2010 Oct;51(10):1805-15. doi: 10.3109/10428194.2010.496506. Review.

46.

Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E.

Volpon L, Osborne MJ, Capul AA, de la Torre JC, Borden KL.

Proc Natl Acad Sci U S A. 2010 Mar 23;107(12):5441-6. doi: 10.1073/pnas.0909877107. Epub 2010 Mar 8.

47.

An antiviral disulfide compound blocks interaction between arenavirus Z protein and cellular promyelocytic leukemia protein.

García CC, Topisirovic I, Djavani M, Borden KL, Damonte EB, Salvato MS.

Biochem Biophys Res Commun. 2010 Mar 19;393(4):625-30. doi: 10.1016/j.bbrc.2010.02.040. Epub 2010 Feb 10.

48.

Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer.

Culjkovic B, Borden KL.

J Oncol. 2009;2009:981679. doi: 10.1155/2009/981679. Epub 2009 Dec 13.

49.

Two fundamentally distinct PCNA interaction peptides contribute to chromatin assembly factor 1 function.

Rolef Ben-Shahar T, Castillo AG, Osborne MJ, Borden KL, Kornblatt J, Verreault A.

Mol Cell Biol. 2009 Dec;29(24):6353-65. doi: 10.1128/MCB.01051-09. Epub 2009 Oct 12.

50.

Control of p53 multimerization by Ubc13 is JNK-regulated.

Topisirovic I, Gutierrez GJ, Chen M, Appella E, Borden KL, Ronai ZA.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12676-81. doi: 10.1073/pnas.0900596106. Epub 2009 Jul 27.

Supplemental Content

Loading ...
Support Center